|
Re: August 2018 Corporate Presentation
|
2
|
BIOASIS TECHNOLOGIES INC
|
Aug 21, 2018 01:00PM
|
|
August 2018 Corporate Presentation
|
2
|
BIOASIS TECHNOLOGIES INC
|
Aug 21, 2018 12:16PM
|
|
Re: ... time lines and yet to come...
|
5
|
Resverlogix Corp.
|
Aug 16, 2018 04:34PM
|
|
Re: time lines and yet to come...
|
3
|
Zenith Epigenetics
|
Aug 16, 2018 04:29PM
|
|
Re: time lines and yet to come...
|
6
|
Zenith Epigenetics
|
Aug 16, 2018 10:57AM
|
|
Re: ... time lines and yet to come...
|
7
|
Resverlogix Corp.
|
Aug 15, 2018 04:13PM
|
|
Re: Reverse Split, the good, bad and in between....
|
9
|
Resverlogix Corp.
|
Aug 15, 2018 01:58PM
|
|
Re: Reverse Split, the good, bad and in between....
|
3
|
Resverlogix Corp.
|
Aug 15, 2018 08:08AM
|
|
ESC 2018 Symposium and Presentation August 25-29, Munich
|
7
|
Resverlogix Corp.
|
Aug 14, 2018 01:55PM
|
|
Re: ABCA1 overexpression worsens colorectal cancer prognosis and this can be ameliorated by apabetalone
|
5
|
Resverlogix Corp.
|
Aug 14, 2018 11:04AM
|
|
Re: "57% relative risk reduction of MACE in patients with diabetes mellitus (DM) and CVD..."
|
5
|
Resverlogix Corp.
|
Aug 14, 2018 09:21AM
|
|
ABCA1 overexpression worsens colorectal cancer prognosis and this can be ameliorated by apabetalone
|
7
|
Resverlogix Corp.
|
Aug 14, 2018 09:11AM
|
|
Re: "57% relative risk reduction of MACE in patients with diabetes mellitus (DM) and CVD..."
|
2
|
Resverlogix Corp.
|
Aug 13, 2018 10:20PM
|
|
Re: Updated Van Leeuwenhoeck Institute Analyst Report and August Fact Sheet
|
3
|
Resverlogix Corp.
|
Aug 13, 2018 01:01PM
|
|
Re: Updated Van Leeuwenhoeck Institute Analyst Report and August Fact Sheet
|
3
|
Resverlogix Corp.
|
Aug 13, 2018 11:11AM
|
|
Re: New shares issued?
|
3
|
Zenith Epigenetics
|
Aug 12, 2018 05:44PM
|
|
Re: What If - Uses of Apabetalone
|
2
|
Resverlogix Corp.
|
Aug 12, 2018 05:34PM
|
|
Re: What If - Uses of Apabetalone
|
5
|
Resverlogix Corp.
|
Aug 12, 2018 02:35PM
|
|
Re: Notice of Meeting and Information Circular on SEDAR
|
3
|
Resverlogix Corp.
|
Aug 11, 2018 01:29PM
|
|
FDA approves Migalastat (Galafold) from Amicus for Fabry disease
|
3
|
Resverlogix Corp.
|
Aug 11, 2018 01:25PM
|
